Phaseline

Targets › MAP2K2

MAP2K2 (Dual specificity mitogen-activated protein kinase kinase 2): drug programs, companies and trials

15 programs from 14 companies in 229 trials: 117 Phase 2, 66 Phase 1, 25 Phase 4, 21 Phase 3; Oncology, Other, Cardiovascular; next expected readout Nov 2026.

Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates the ERK1 and ERK2 MAP kinases (By similarity). (UniProt, P36507)

Open in Phaseline: the race on MAP2K2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisTrametinib
Dual specificity mitogen-activated protein kinase kinase 2 inhibitor; Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase; MEK1/2 inhibitor
MAP2K2, MAP2K1Phase 4Diffuse Astrocytoma; Melanoma; Differentiated Thyroid Cancer (DTC); EGFR-mutant Non-small Cell Lung Cancer …Nov 2026
University of California, San FranciscoIntravenous TXA
Interleukin-23 inhibitor
ADRB2, AGTR1, IL12B, IL23A, PDCD1, NR3C1, HTR2A, MAP2K1, MAP2K2, MS4A1, CHRM3, CHRM2, ADRB3, OPRM1, CYP19A1, CHRNB2, CHRNA4Phase 4Child Mortality; Relapsing Multiple Sclerosis; Menstrual Regulation; Secondhand Smoke …Dec 2026
PfizerBinimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 4Solid Tumors; MelanomaJul 2029
Pierre Fabre MedicamentBinimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Melanoma; Non-Small Cell Lung Cancer; Solid Tumor, Adult; Solid Tumor …Dec 2026
Verastemavutometinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Low Grade Serous Ovarian Cancer; Low Grade Ovarian Serous Adenocarcinoma; Non Small Cell Lung Cancer; KRAS Activating Mutation …Dec 2026
Shanghai Kechow Pharmatunlametinib
MEK1/2 inhibitor
MAP2K1, MAP2K2Phase 3Colorectal Cancer Metastatic; Melanoma; Melanoma Advanced; Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS Mutation …Dec 2026
AstraZenecaSelumetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 3Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV; Neurofibromatosis 1; Advanced Non Small Cell Lung Cancer; Tumor …Dec 2026
Chia Tai Tianqing Pharmaceutical GroupTQ-B3234 capsules
Selective MEK1/2 inhibitor
MAP2K1, MAP2K2Phase 3Plexiform NeurofibromaDec 2027
RocheCobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Non-small Cell Lung Cancer; Melanoma; Metastatic Distal Bile Duct Adenocarcinoma; Chronic Myelomonocytic Leukemia (CMML) …Nov 2026
RocheCobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Non-Small Cell Lung Cancer; Ovarian CancerJun 2027
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyMirdametinib (PD-0325901)
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Plexiform Neurofibroma; Healthy; Slow-Flow Vascular Malformation; Advanced Unresectable Melanoma …Dec 2028
Hanmi Pharmaceutical CompanyCobimetinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 2Advanced or Metastatic MelanomaSep 2029
Merck KGaAMirdametinib
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 1HealthyNov 2026
Recursion PharmaceuticalsTak-733 (REC-4881)
Dual specificity mitogen-activated protein kinase kinase 1 inhibitor; Dual specificity mitogen-activated protein kinase kinase 2 inhibitor
MAP2K1, MAP2K2Phase 1Familial Adenomatous PolyposisJun 2027
Pasithea TherapeuticsPAS-004
MEK 1/2 inhibitor
MAP2K1, MAP2K2Phase 1RAS Mutation; NF1 MutationSep 2027

Conditions

Melanoma (8) Advanced Lymphoma (6) Neurofibromatosis 1 (5) Neurofibromatosis Type 1 (3) Low Grade Glioma (3) Non-small Cell Lung Cancer (3) Non-Small Cell Lung Cancer (3) Metastatic Malignant Neoplasm in the Brain (3) Nicotine Dependence (3) Metastatic Melanoma (2) Solid Tumor, Adult (2) Solid Tumor (2)

Modalities

small molecule (12), mixed (3)

Companies

Roche (2) AstraZeneca (1) Pierre Fabre Medicament (1) Shanghai Kechow Pharma (1) Pasithea Therapeutics (1) Novartis (1) Merck KGaA (1) SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany (1) University of California, San Francisco (1) Verastem (1) Pfizer (1) Chia Tai Tianqing Pharmaceutical Group (1) Recursion Pharmaceuticals (1) Hanmi Pharmaceutical Company (1)

Related targets

MAP2K1 (15) ADRB2 (1) AGTR1 (1) IL12B (1) IL23A (1) PDCD1 (1) NR3C1 (1) HTR2A (1) MS4A1 (1) CHRM3 (1) CHRM2 (1) ADRB3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.